/PFND

PFND Stock - Pathfinder Cell Therapy, Inc.

Q: What is the analyst price target for PFND?

Analyst price target information is not currently available for PFND.

Q: What is PFND's market cap?

Market capitalization information is not currently available for PFND.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Jan 12

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PFND

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2010

FY2011

FY2012

FY2013

FY2014

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-24.33

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2014	FY2013	FY2012	FY2011	FY2010
Revenue	N/A	$54,000	$114,000	$73,000	$344,000
Gross Profit	N/A	$17,000	$64,000	$47,000	$252,000
Gross Margin	N/A	31.5%	56.1%	64.4%	73.3%
Operating Income	$-1,119,000	$-1,599,000	$-2,060,000	$3.93M	$-2,499,000
Net Income	$-1,669,000	$-1,811,000	$-2,252,000	$-18,922,000	$-2,076,000
Net Margin	N/A	-3353.7%	-1975.4%	-25920.5%	-603.5%
EPS	$-0.00	$-0.00	$-0.00	$-0.04	$-0.00

Company Overview

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Visit Website

Frequently Asked Questions about PFND

What is PFND's current stock price?

Pathfinder Cell Therapy, Inc. (PFND) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for PFND?

No analyst price targets are currently available for this stock.

What sector is Pathfinder Cell Therapy, Inc. in?

Pathfinder Cell Therapy, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is PFND's market cap?

Pathfinder Cell Therapy, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does PFND pay dividends?

No, Pathfinder Cell Therapy, Inc. does not currently pay a dividend to shareholders.